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HEYMAN ET AL . BRIEF DEFINITIVE REPORT FIGURE 1 . Effect of complement depletion on IgM-induced enhancement of the antibody response in mice. Two groups of CBA/Ca mice were injected intraperitoneally with CVF. Two control groups received PBS in the same regimen. 2 h after the last CVF injection all mice were bled from their tails in order to titer C3 . Another2 h later, one CVF group and one control group received intravenous injections of 0.1 ml murine, polyclonal IgM-antiSRBC (hemolytic titer 2,048) . 1 h later all groups were immunized intravenously with 4 x 10 5 SRBC (10 mice in two different experiments) together with 2 x 10 5 HRBC (horse erythrocytes) . ("") p < 0.001 vs. the respective control group. Mice injected only with IgM-antiSRBC generated 65 PFC/spleen (not shown). No significant enhancement of PFC anti-HRBC was found (not shown) .
Sera from the individual mice (bled 7 d before and 2 h after CVF treatment) were assayed for C3 by radial immunodiffusion against goat anti-mouse C3 antibodies . Mean titer was 6.3 ± 1.3 (SEM) after and 45 .6 ± 6.5 before CVF treatment.
the first injection and 2 h after the last . C3 levels in sera were assayed by radial immunodiffusion using a goat anti-mouse C3 antiserum (CooperBiomedical, Inc., Malvern, PA).
Immunizations . Groups of at least four mice were immunized as described in the figure legends.
Enzyme-linked Immunosorbent Assay. SRBC-specific IgG antibodies in sera were assayed in an ELISA, as described elsewhere (9) . PFC Assay. A modified version of the Jerne hemolytic plaque assay was performed (3). The p values were estimated by Student's t test .
Results and Discussion
In vivo administration of CVF causes transient depletion of plasma C3 to <5% of normal due to activation ofC3 via the alternative pathway (10) . Mice were treated with CVF and then challenged with polyclonal IgM-antiSRBC and SRBC . This procedure abrogated the five-to sixfold enhancing effect on the direct PFC response of IgM seen in normal mice immunized with 4 x 105 SRBC (Fig. 1) . Moreover, no elevation of the IgG-anti-SRBC levels in sera of CVF and IgM-treated mice was detected (Table 1) . CVF from Naja haje does not deplete complement factors that act subsequent to C3 in the complement pathway (11) . These data therefore indicate that the early complement factors are crucial in the enhancing process . To confirm this, AKR mice, which are genetically deficient of C5 (12), were injected with SRBC-specific IgM and SRBC and the enhancement of the anti-SRBC response in these mice was compared with that in similarly treated CBA/Ca mice having normal C5 levels . It is clearly demonstrated that IgM is a potent enhancer also of the humoral immune response in AKR mice (Fig . 2) . Next, we compared the effects on the antiSRBC response of a monoclonal TNR specific IgM and a mutant of this antibody, IgM13, which has <1% the normal capacity to activate complement due to a single amino acid substitution (8) . Mice were immunized with SRBC TNP with or without IgM-anti TNP of either the wild or mutant type, with the same hemagglutinating titers. Since IgM is known to enhance the response against all different epitopes on an antigen equally well (3), the PFC response against SRBC was measured . The wild-type antibody enhanced the response in a dose-dependent fashion, whereas the mutant antibody failed to induce any significant enhancement (Fig . 3) .
In a model for IgM-mediated enhancement of the humoral immune response there are two main concepts to consider. The first is the central role of complement in induction of immunological memory and normal humoral responses (reviewed in references 13, 14) . These effects have been ascribed to C3 (14) . Also, patients with C4 deficiency respond poorly to T-dependent antigens and do not develop immunological memory (15) . Our results on the effect of CVF treatment on the IgM enhancement are most likely due to decreased C3 levels since we used CVF from Egyptian cobra (Naja haje) and IgM is an efficient enhancer ofthe antiSRBC response in AKR mice. The second concept is the important role of the spleen in immune responses affected by C3 and/or IgM potentiation . Complement is essential for efficient localization of antigen to the spleen (16, 17) . The IgM-mediated enhancement is paralleled by an increased level of SRBC in the spleen (2) . Splenectomized mice (Heyman, B., unpublished data) as well as patients with hereditary aplasia of the spleen (18) are poor responders to intravenously administered SRBC, the route normally used in IgM enhancement studies .
We propose the following model for IgM enhancement of responses against particulate antigens. In the spleen, complexes of antigen-IgM-activated C3 fragments are trapped more efficiently than antigen alone on the follicular dentritic cells (FDC), which carry Cab receptors (19). The trapped immune complexes then capture B cells carrying antigen-specific as well as C3 receptors . Crosslinked C3 is known to stimulate activated B cells to proliferation and Ig secretion (20) . Additional help to these B cells may be provided by antigen-specific T helper cells that are activated more efficiently due to increased concentrations of antigen, and possibly by IL-1 secretion by the FDC.
Thus, the mechanism behind IgM-mediated enhancement would be a more efficient presentation of antigen and more efficient activation ofantigen sensitive B cells. This explains why the same fine specificity (3) and isotype distribution (21) are found in IgM-enhanced and control responses . Moreover, IgM is known to potentiate (1) and CVF to suppress (22) the immune response only to suboptimal antigen doses .
Interestingly, IgG has been shown to enhance the primary response (23) as well as the induction of memory (17) to soluble antigens . This has been ascribed to the ability of the IgG antibodies to activate complement, and a hypothesis similar to ours was proposed to explain the results (17) .
Summary
The ability of IgM antibodies to specifically enhance the thymus-dependent humoral immune response to particulate antigens is well documented. We have used two approaches to test whether complement factors play a role in this process . First, mice were depleted of C3 by treatment with cobra venom factor (CVF) and then immunized with SRBC with or without IgM-antiSRBC . CVF treatment severely impaired the capacity ofIgM to induce an enhanced antiSRBC response. Moreover, it was shown that IgM can potentiate the response in C5-deficient AKR mice, thus demonstrating that the complement factors acting before C5 are the crucial ones. A second test compared the enhancing properties oftwo monoclonal IgM-antiTNP antibodies where, because of a point mutation in the g chain constant region, one of the antibodies is impaired in its capacity to activate complement. We show that the mutant antibody lacks the enhancing properties of the wild-type IgM .
Activation of C3 by IgM antibodies as well as localization of antigen in the spleen seem to be necessary steps in the IgM-mediated enhancement of antibody responses. Our data offer an explanation to the immunosuppression described in CVF-treated animals as well as the low humoral immune responses in certain hereditary complement deficiencies . It is suggested that IgM indeed has an important physiological function in enhancing antibody responses to foreign substances . 
